ClinicalTrials.gg
RecruitingNCT06928818Updated Apr 23, 2026

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

An observational study in Cancer of Breast, Trastuzumab Emtansine and Trastuzumab Deruxtecan, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Seoul National University Hospital · Observational

How we know · 4 judgments

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Breast Neoplasms by Seoul National University Hospital — 13 open to participants now, 21 under way, 3 of them phase 3. Breast Neoplasms · Seoul National University Hospital.

Planned enrollment
17th of 22
100 · median 352
Started
2025
with 2 others
Observational
22 of 50
5 open now
Primary completion
2028-09
later than 19 of 20 live
Registered
50th of 50
by date

Among the 50 studies in Breast Neoplasms by Seoul National University Hospital, this one is the 17th largest by planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2025, is one of 22 observational ones, reaches primary completion later than 19 of the 20 other live ones, and was the 50th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 50 studies in Breast Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Breast Neoplasms by Seoul National University Hospital, or all of them as a file.
02

Study summary

Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea

03

Conditions studied

  • Cancer of Breast
  • Trastuzumab Emtansine
  • Trastuzumab Deruxtecan

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

  • Signed Informed Consent Form, when the patient is alive and not lost to follow- up.
  • Age ≥ 19 years old.
  • Histologically or cytologically confirmed, HER2-positive advanced breast cancer which is either locally advanced precluding resection or metastatic.
  • Prior treatment with T-Dxd in the advanced setting
  • Intention to treat with T-DM1 as next therapy upon progression from T-Dxd

Patients who meet any of the following criteria will be excluded from study entry:

  • Any systemic treatment, other than T-DM1, for breast cancer after T-Dxd (With an exception, endocrine agents not in combination with cytotoxics or antibody-drug conjugates will be permitted in the study)
  • Has been previously treated with T-DM1 for advanced breast cancer
  • Has been previously treated with 4 or more lines of therapy for advanced breast cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -positive, advanced (unresectable locally advanced or ) breast cancer
  • Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting
  • Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression

Exclusion criteria

Exclusion Criteria:

  • Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)
  • Has been previously treated with T-DM1 for advanced breast cancer
  • Has been previously treated with 4 or more for advanced breast cancer

    • Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

This study also gives Trastuzumab deruxtecanStudies of Trastuzumab deruxtecanTrastuzumab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Ado-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. progression-free survival (PFS)

    PFS will be assessed by physicians as per routine clinical practice. CT and/or MRI scans will be at baseline and every 2-4 cycles at the treating physician's discretion, reflecting the observational study design.

    Time frame: PFS is defined as the time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, assessed up to 12 months.

Secondary outcomes

  1. objective response rate (ORR)

    • objective response rate (ORR)

    Time frame: 12-month

  2. 12-month survival rate

    12-month survival rate

    Time frame: 12-month

  3. time-to-discontinuation (TTD)

    time-to-discontinuation (TTD)

    Time frame: 12-month

  4. time-to-next-line-treatment (TTNT)

    time-to-next-line-treatment (TTNT), disregarding endocrine treatments as the maintenance

    Time frame: 12-month

  5. Duration of therapy (DoT)

    Duration of therapy (of T-DM1) will be compared to the duration of previous therapy (T-DXd) to ensure the comparability of each treatments reflecting the tumor biology and clinical course.

    Time frame: 12-month

  6. Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events

    Time frame: 12-month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Sep 2028, 43 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 43 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 15, 2025
StartActual
Feb 26, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2029
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06928818
Responsible party
Kyung-Hun Lee (Principal Investigator, Seoul National University Hospital) — Principal investigator
First posted
Apr 15, 2025
Start date
Feb 26, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Apr 23, 2026

Study contacts

Kyung-Hun Lee, MD, PhD
Contact
kyunghunlee@snu.ac.kr
82-2-2072-7207

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion